Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man

Y. A. Kesaniemi, Scott M Grundy

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Mechanisms for the hypolipidemic action of gemfibrozil were examined in seven patients with hypertriglyceridemia. In addition, seven hyperlipidemic patients were studied with and without clofibrate treatment to compare the mechanisms by which these two drugs lower plasma triglyceride levels. All patients were studied on a metabolic ward. The first month was a control period, followed by one month of either gemfibrozil or clofibrate therapy. During treatment with gemfibrozil, plasma total triglyceride levels decreased by an average of 51%, and triglyceride levels in very low-density lipoproteins (VLDLs) fell by 57%. Transport rates of VLDL triglyceride were determined by multicompartmental analysis following injection of tritiated glycerol as a precursor. Gemfibrozil decreased transport (production) of VLDL triglyceride by an average of 28% and increased the fractional catabolic rate (FCR) of VLDL triglyceride by 92%. Clofibrate reduced plasma total triglyceride values on an average of 32% and VLDL triglyceride values by 38%. In contrast to gemfibrozil, clofibrate did not change transport rates of VLDL triglyceride but increased the fractional catabolic rate of VLDL triglyceride by 35%. Gemfibrozil thus decreased production of VLDL triglyceride and enhanced its clearance, while clofibrate only decreased clearance of VLDL triglyceride. On the average, plasma cholesterol levels did not fall during gemfibrozil treatment, but levels of cholesterol in high-density lipoproteins and in low-density lipoproteins increased by 31% and 11%, respectively. The drug produced a 30% increase in fecal excretion of neutral steroids and a 37% decrease in fecal excretion of bile acids. Outputs of total neutral steroids and net cholesterol balance thus remained unchanged.

Original languageEnglish (US)
Pages (from-to)2241-2246
Number of pages6
JournalJournal of the American Medical Association
Volume251
Issue number17
DOIs
StatePublished - 1984

Fingerprint

Gemfibrozil
Clofibrate
Triglycerides
Cholesterol
Steroids
very low density lipoprotein triglyceride
VLDL Lipoproteins
Hypertriglyceridemia
Therapeutics
Bile Acids and Salts
LDL Lipoproteins
Pharmaceutical Preparations
Glycerol
HDL Cholesterol
Injections

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. / Kesaniemi, Y. A.; Grundy, Scott M.

In: Journal of the American Medical Association, Vol. 251, No. 17, 1984, p. 2241-2246.

Research output: Contribution to journalArticle

@article{5de90f9c71ed491a8fd0cf2d8ce7e439,
title = "Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man",
abstract = "Mechanisms for the hypolipidemic action of gemfibrozil were examined in seven patients with hypertriglyceridemia. In addition, seven hyperlipidemic patients were studied with and without clofibrate treatment to compare the mechanisms by which these two drugs lower plasma triglyceride levels. All patients were studied on a metabolic ward. The first month was a control period, followed by one month of either gemfibrozil or clofibrate therapy. During treatment with gemfibrozil, plasma total triglyceride levels decreased by an average of 51{\%}, and triglyceride levels in very low-density lipoproteins (VLDLs) fell by 57{\%}. Transport rates of VLDL triglyceride were determined by multicompartmental analysis following injection of tritiated glycerol as a precursor. Gemfibrozil decreased transport (production) of VLDL triglyceride by an average of 28{\%} and increased the fractional catabolic rate (FCR) of VLDL triglyceride by 92{\%}. Clofibrate reduced plasma total triglyceride values on an average of 32{\%} and VLDL triglyceride values by 38{\%}. In contrast to gemfibrozil, clofibrate did not change transport rates of VLDL triglyceride but increased the fractional catabolic rate of VLDL triglyceride by 35{\%}. Gemfibrozil thus decreased production of VLDL triglyceride and enhanced its clearance, while clofibrate only decreased clearance of VLDL triglyceride. On the average, plasma cholesterol levels did not fall during gemfibrozil treatment, but levels of cholesterol in high-density lipoproteins and in low-density lipoproteins increased by 31{\%} and 11{\%}, respectively. The drug produced a 30{\%} increase in fecal excretion of neutral steroids and a 37{\%} decrease in fecal excretion of bile acids. Outputs of total neutral steroids and net cholesterol balance thus remained unchanged.",
author = "Kesaniemi, {Y. A.} and Grundy, {Scott M}",
year = "1984",
doi = "10.1001/jama.251.17.2241",
language = "English (US)",
volume = "251",
pages = "2241--2246",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "17",

}

TY - JOUR

T1 - Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man

AU - Kesaniemi, Y. A.

AU - Grundy, Scott M

PY - 1984

Y1 - 1984

N2 - Mechanisms for the hypolipidemic action of gemfibrozil were examined in seven patients with hypertriglyceridemia. In addition, seven hyperlipidemic patients were studied with and without clofibrate treatment to compare the mechanisms by which these two drugs lower plasma triglyceride levels. All patients were studied on a metabolic ward. The first month was a control period, followed by one month of either gemfibrozil or clofibrate therapy. During treatment with gemfibrozil, plasma total triglyceride levels decreased by an average of 51%, and triglyceride levels in very low-density lipoproteins (VLDLs) fell by 57%. Transport rates of VLDL triglyceride were determined by multicompartmental analysis following injection of tritiated glycerol as a precursor. Gemfibrozil decreased transport (production) of VLDL triglyceride by an average of 28% and increased the fractional catabolic rate (FCR) of VLDL triglyceride by 92%. Clofibrate reduced plasma total triglyceride values on an average of 32% and VLDL triglyceride values by 38%. In contrast to gemfibrozil, clofibrate did not change transport rates of VLDL triglyceride but increased the fractional catabolic rate of VLDL triglyceride by 35%. Gemfibrozil thus decreased production of VLDL triglyceride and enhanced its clearance, while clofibrate only decreased clearance of VLDL triglyceride. On the average, plasma cholesterol levels did not fall during gemfibrozil treatment, but levels of cholesterol in high-density lipoproteins and in low-density lipoproteins increased by 31% and 11%, respectively. The drug produced a 30% increase in fecal excretion of neutral steroids and a 37% decrease in fecal excretion of bile acids. Outputs of total neutral steroids and net cholesterol balance thus remained unchanged.

AB - Mechanisms for the hypolipidemic action of gemfibrozil were examined in seven patients with hypertriglyceridemia. In addition, seven hyperlipidemic patients were studied with and without clofibrate treatment to compare the mechanisms by which these two drugs lower plasma triglyceride levels. All patients were studied on a metabolic ward. The first month was a control period, followed by one month of either gemfibrozil or clofibrate therapy. During treatment with gemfibrozil, plasma total triglyceride levels decreased by an average of 51%, and triglyceride levels in very low-density lipoproteins (VLDLs) fell by 57%. Transport rates of VLDL triglyceride were determined by multicompartmental analysis following injection of tritiated glycerol as a precursor. Gemfibrozil decreased transport (production) of VLDL triglyceride by an average of 28% and increased the fractional catabolic rate (FCR) of VLDL triglyceride by 92%. Clofibrate reduced plasma total triglyceride values on an average of 32% and VLDL triglyceride values by 38%. In contrast to gemfibrozil, clofibrate did not change transport rates of VLDL triglyceride but increased the fractional catabolic rate of VLDL triglyceride by 35%. Gemfibrozil thus decreased production of VLDL triglyceride and enhanced its clearance, while clofibrate only decreased clearance of VLDL triglyceride. On the average, plasma cholesterol levels did not fall during gemfibrozil treatment, but levels of cholesterol in high-density lipoproteins and in low-density lipoproteins increased by 31% and 11%, respectively. The drug produced a 30% increase in fecal excretion of neutral steroids and a 37% decrease in fecal excretion of bile acids. Outputs of total neutral steroids and net cholesterol balance thus remained unchanged.

UR - http://www.scopus.com/inward/record.url?scp=0021276830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021276830&partnerID=8YFLogxK

U2 - 10.1001/jama.251.17.2241

DO - 10.1001/jama.251.17.2241

M3 - Article

C2 - 6368883

AN - SCOPUS:0021276830

VL - 251

SP - 2241

EP - 2246

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 17

ER -